Phase 3 Mania Clinical Trials
9 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bipolar DisorderMania
Bristol-Myers Squibb424 enrolled103 locationsNCT07140913
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled74 locationsNCT06951711
Recruiting
Phase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bipolar Disorder Type I With Mania
Bristol-Myers Squibb450 enrolled170 locationsNCT06929273
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bipolar-I Disorder With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled63 locationsNCT06951698
Recruiting
Phase 3
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.
Leishmaniasis, Cutaneous
Universidad de Antioquia96 enrolled1 locationNCT06822478
Recruiting
Phase 3
Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan
Old World Cutaneous Leishmaniasis
Medecins Sans Frontieres, Netherlands832 enrolled2 locationsNCT04268524
Recruiting
Phase 2Phase 3
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
Leishmaniasis, MucocutaneousLeishmaniasis; Brazilian
University of Brasilia100 enrolled1 locationNCT06040489
Completed
Phase 2Phase 3
Liposomal amphotericin B for the treatment of Nepalese patients with visceral leishmaniasis.
Visceral Leishmaniasis
The United Nations Children's Fund (UNICEF)/ The United Nations Development Programme (UNDP) /World Bank /World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases (TDR)35 enrolled1 locationACTRN12610000130066
Active
Phase 2Phase 3
Liposomal amphotericin B for the treatment of Bangladeshi patients with visceral leishmaniasis.
Visceral leishmaniasis (VL)
The United Nations Children's Fund (UNICEF)/ The United Nations Development Programme (UNDP) /World Bank /World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases (TDR)35 enrolled1 locationACTRN12609001029280